Status:
WITHDRAWN
Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Hemophilia A
Eligibility:
MALE
18-64 years
Phase:
PHASE4
Brief Summary
The purpose of the study is to compare the pharmacokinetic parameters of ReFacto and Advate, using the chromogenetic substrate assay to measure plasma Factor VIII activity in plasma.
Eligibility Criteria
Inclusion
- Severe hemophilia A
- Previously treated patients with at least 150 exposure days to any Factor VIII product
Exclusion
- Hypersensitivity to any recombinant Factor VIII product
- History of or current Factor VIII inhibitor
- Bleeding episode or other reason requiring Factor VIII treatment within 3 days of study
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00168051
Start Date
April 1 2005
End Date
November 1 2005
Last Update
September 25 2018
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington D.C., District of Columbia, United States, 20007
2
Atlanta, Georgia, United States, 30322
3
Iowa City, Iowa, United States, 52242
4
New Orleans, Louisiana, United States, 70112